Zoster vaccine live for the prevention of shingles in the elderly patient

Clinical Interventions in Aging

Volumn 3, Issue 2, 2008, Pages 241-250

  Zussman, Jamie ^a   Young, Lorraine ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Herpes zoster; Postherpetic neuralgia; Shingles; Zostavax; Zoster vaccine

Indexed keywords

ANTICONVULSIVE AGENT; ANTIVIRUS AGENT; CHICKENPOX VACCINE; CORTICOSTEROID; DOPAMINE RECEPTOR STIMULATING AGENT; GABAPENTIN; LIDOCAINE; NORTRIPTYLINE; OPIATE; PLACEBO; PREDNISONE; PREGABALIN; STEROID; TRAMADOL; VARICELLA ZOSTER VACCINE;

AGED; ASTHMA; CLINICAL FEATURE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DRUG CONTRAINDICATION; DRUG INDICATION; ERYTHEMA; GERIATRIC PATIENT; GOODPASTURE SYNDROME; HERPES ZOSTER; HUMAN; IMMUNOCOMPROMISED PATIENT; INFECTION COMPLICATION; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE REACTION; MORBIDITY; PAIN; PARESTHESIA; POPULATION RISK; POSTHERPETIC NEURALGIA; PRURITUS; RASH; RECURRENT INFECTION; REVIEW; RHEUMATIC POLYMYALGIA; RISK REDUCTION; SWELLING; VACCINATION REACTION; VIRUS IMMUNITY; VIRUS REACTIVATION;

AGED; HERPES ZOSTER; HERPES ZOSTER VACCINE; HERPESVIRUS 3, HUMAN; HUMANS; NEURALGIA, POSTHERPETIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VIRUS LATENCY;

EID: 47849110904     PISSN: 11769092     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (63)

1. Adour KK. 1994. Otological complications of herpes zoster. Ann Neurol, 35(Suppl):S62-4.
2. Brisson M, Edmunds WJ, Law B, et al. 2001. Epidemiology of varicella zoster virus infection in Canada and the United Kingdom. Epidemiol Infect, 127:305-14.
3. Buchbinder SP; Katz MH; Hessol NA, et al. 1992. Herpes zoster and human immunodeficiency virus infection. J Infect Dis, 166:1153-6.
4. Burke MS. 2007. Herpes Zoster Vaccine; Clinical trial evidence. J Am Osteopath Assoc, 107:S14-S18.
5. Caranasos GJ, Stewart RB, Cluff LE. 1974. Drug-induced illness leading to hospitalization. JAMA, 228:713-17.
6. Chaves S. 2007a. Update on safety of Herpes Zoster Vaccine. Presented at the Advisory Committee on Immunization Practices meeting, Atlanta, GA. June 30, 2006 [online]. Accessed October 11, 2007. URL: http://www.cdc.gov/vaccines/recs/acip/downloads/mtg-slides-jun07/ 12-zoster-chavez.pdf
7. Chaves SS, Gargiullo P, Zhang JX, et al. 2007b. Loss of vaccine induced immunity to varicella over time. N Engl J Med, 356:1121-9.
8. Chaves SS, Santibanez TA, Gargiullo P, et al. 2007c. Chickenpox exposure and herpes zoster disease incidence in older adults in the US Public Health Rep, 122:155-9.
9. Cohen JI, Brunell PA, Straus SE, et al. 1999. Recent advances in varicella-zoster virus infection. Ann Intern Med, 130:922-32.
10. Davis MM, Patel MS, Gebremariam A. 2004. Decline in varicella-related hospitalizations and expenditures for children and adults after introduction of varicella vaccine in the United States. Pediatrics, 114:786-92.
11. Dworkin RH, White R, O'Conner AB, et al. 2007. Healthcare costs of acute and chronic pain associated with a diagnosis of herpes zoster. J Am Geriatr Soc, 55:1168-75.
12. Eaglestein WH, Katz R, Brown JA. 1970. The effects of early corticosteroid therapy on the skin eruption and pain of herpes zoster. JAMA, 211:1681-3.
13. Esmann V, Geil JP, Kroon S, et al. 1987. Prednisolone does not prevent post-herpetic neuralgia. Lancet, 2:126-9.
14. Galil K, Choo PW, Donahue JG, et al. 1997. The sequelae of herpes zoster. Arch Intern Med, 157:1209-13.
15. Galbraith AW. 1983. Prevention of post-herpetic neuralgia by amantadine hydrochloride (Syrnmetrel). Br J Clin Pract, 37:304-6.
16. Garweg J, Behnke M. 1997. Varicella-zoster virus is strongly associated with atypical necrotizing herpetic retinopathies. Clin Infect Dis, 24:603-8.
17. Gilden DH, Kleinschmidt-DeMasters BK, LaGuardia JJ, et al. 2000. Neurologic complications of the reactivation of varicella-zoster virus. N Engl J Med, 342:635-45.
18. Glesby MJ, Moore RD, Chaisson RE. 1993. Herpes zoster in patients with advanced human immunodeficiency virus infection treated with zidovudine. Zidovudine Epidemiology Study Group. J Infict Dis, 168:1264-8.
19. Gnann JW, Whitley RJ. 2002. Herpes Zoster. N Engl J Med, 347:340-6.
20. Hata A, Asanuma H, Rinki M, et al. 2002. Use of an inactivated varicella vaccine in recipients of hematopoietic-cell transplants. N Engl J Med, 347:26-34.
21. Häusler M, Schaade L, Kemény S, et al. 2002, Encephalitis related to primary varicella-zoster virus infection in immunocompetent children. J Neurol Sci, 195:111-16.
22. Hope-Simpson RE. 1965. The nature of herpes zoster: A long-term study and a new hypothesis. Proc R Soc Med, 58:9-20.
23. Hornberger J, Robertus K. 2006. Cost-effectiveness of a vaccine to prevent herpes zoster and post-herpetic neuralgia in older adults. Ann Intern Med, 145:317-25.
24. Im M, Kim BJ, Seo YJ, et al. 2007. Complete ophthalmoplegia after herpes zoster. Clin Exp Dermatol, 32:162-4.
25. Insinga RP, Itzler RF, Pellissier JM, et al. 2005. The Incidence of herpes zoster in a United States administrative database. J Gen Intern Med, 20:748-53.
26. Katz J, Melzack R. 1999. Measurement of pain. In: Surgical Clinics of North America. Elsevier: Pub, 231-52.
27. Kawajiri S, Tani M, Noda K, et al. 2007. Segmental zoster paresis of limbs: Report of three cases and review of literature. Neurologist, 13:313-17.
28. Keczkes K, Basheer AM. 1980. Do corticosteroids prevent post-herpetic neuralgia? Br J Dermatol, 102:551-5.
29. Kilgore PE, Kruszon-Moran D, Seward JF, et al. 2003. Varicella in Americans from NHANES III: Implications for control through routine immunization. J Med Virol, 70: S111-S118.
30. Kimberlin DW, Whitley RJ. 2007. Varicella-Zoster vaccine for the prevention of herpes zoster. N Engl J Med, 356:1338-43.
31. Kost RG, Straus SE. 1996. Post-herpetic neuralgia - pathogenesis, treatment, and prevention. N Engl J Med, 335:32-42.
32. Kraft JN, Shaw JC. 2006. Varicella infection casued by Oka strain vaccine in a heart transplant recipient. Arch Dermatol, 142:943-5.
33. Kramer JM, LaRussa P, Tsai WC, et al. 2001. Disseminated vaccine strain varicella as the acquired immunodeficiency syndrome-defining illness in a previously undiagnosed child. Pediatrics, 108:E39.
34. Kroger AT, Atkinson WL, Marcuse EK, et al. 2006. General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep, 55:1-48.
35. Legami VD, Gianino MM, Atti MCD, et al. 2007. Epidemiology and costs of herpes zoster: Background data to estimate the impact of vaccination. Vaccine, 25:7598-604.
36. Levin MJ. 2001. Use of varicella vaccines to prevent herpes zoster in older individuals. Arch Virol Suppl, 17:151-60.
37. Levin MJ, Smith JG, Kaufhold RM, et al. 2003. Decline in varicella-zoster virus (VZV)specific cell-mediated immunity with increasing age and boosting with a high-dose VZV vaccine. J Infect Dis, 188:1336-44.
38. Levy O, Orange JS, Hibberd P, et al. 2003. Disseminated varicella infection due to the vaccine strain of varicella-zoster virus, in a patient with a novel deficiency in natural killer T cells. J Infect Dis, 188:948-53.
39. Marin M, Güris D, Chaves SS, et al. 2007. Prevention of varicella, recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR, 56:1-40.
40. Merck. 2007. Zoster Vaccine Live: Full prescribing information for health-care professionals [online]. Accessed June 4, 2007. URL: http://www.zostavax.com.
41. Messonnier ML, Zhou F. 2006. Review of economic studies of varicella zoster vaccine. Presentation to the ACIP, Atlanta, 25 October.
42. Nguyen HQ, Jumaan AO, Seward JF. 2005. Decline in mortality due to varicella after implementation of varicella vaccination in the United States. N Engl J Med, 352:450-8.
43. Opstelten W, Mauritz JW, de Wit NK, et al. 2002. Herpes zoster and postherpetic neuralgia: incidence and risk indicators using a general practice research database. Family Practice, 19:471-5.
44. Oxman MN, Levin MJ, Johnson GR, et al. 2005. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med, 352:2271-84.
45. Oxman MN. 2007. Vaccination to prevent herpes zoster and postherpetic neuralgia. Hum Vaccin, 3:64-8.
46. Pellissier J; The Zostavax Outcomes Research Team. 2006. Evaluation of the cost-effectiveness in the US of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Presented at the advisory committee on immunization practices meeting, Atlanta, GA, June 30, 2006. Record of the proceedings. pp. 60-3 [online]. Accessed 2007. URL: http://www.cdc.gov/vaccines/recs/acip/downloads/min-jun06.pdf.
47. Petursson G, Helgason S, Gudmundsson S, et al. 1998. Herpes zoster in children and adolescents. Pediatr Infect Dis J, 10:905-8.
48. Rice AS, Maton S; Postherpetic Neuralgia Study Group. 2001. Gabapentin in post-herpetic neuralgia: a randomized, double blind, placebo-controlled trial. Pain, 94:215-24.
49. Rothberg MB, Virapongse A, Smith KJ. 2007. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Clin Infect Dis, 44:1280-8.
50. Rowbotham M, Harden N, Stacey B, et al. 1998. Gabapentin for the treatment of postherpetic neuralgia: a randomized, controlled trial. JAMA, 280:1837-42.
51. Saarto T, Wiffen P. 2007. Antidepressants for neuropathic pain. Cochrane Database Syst Rev, 4:CD005454.
52. Schmader K. 2007. Herpes zoster and postherpetic neuralgia in older adults. Clin Geriatr Med, 23:615-32.
53. Schmader KE, Sloane R, Pieper C, et al. 2007b. The impact of acute herpes zoster pain and discomfort on functional status and quality of life in older adults. Clin J Pain, 23:490-6.
54. Schmader KE, George LK, Hamilton JD. 1995. Racial differences in the occurrence of herpes zoster. J Infect Dis, 171:701-5.
55. Taha Y; Scott FT; Parker SP, et al. 2006. Reactivation of 2 genetically distinct varicella-zoster viruses in the same individual. Clin Infect Dis, 43:1301-3.
56. Takayama N, Takayama M, Takita J. 2000. Herpes zoster in healthy children immunized with varicella vaccine. Pediatr Infect Dis J, 19:169-70.
57. Tassone DM, Boyce E, Guyer J, et al. 2007. Pregabalin: A novel 7-aminobutyric acid analogue in the treatment of neuropathic pain, partial-onset seizures, and anxiety disorders. Clin Ther, 29:26-48.
58. Tyring SK, Diaz-Mitoma F, Padget LG, et al. 2007. Safety and tolerability of a high-potency zoster vaccine in adults >50 years of age. Vaccine, 25:1877-83.
59. [USCB] United States Census Bureau Homepage. 2004. Table 2a. Projected population of the U.S. by age and sex: 2000 to 2050 [online]. Accessed 2007. URL: http://www.census.gov/ipc/www/usinterimproj/.
60. Vander Straten M, Carrasco D, Lee P, et al. 2001. Reduction of Postherpetic neuralgia in HZ. J Cutan Med Surg, 5:409-16.
61. Wood MJ, Johnson RW, McKendrick MW, et al. 1994. A randomized trial of Acyclovir for 7 and 21 days with and without prednisolone for treatment of acute herpes zoster. N Engl J Med, 330:896-900.
62. [WHO] World Health Organization. 2007. Definition of an older or elderly person [online]. Accessed October 15, 2007. URL: http://www.who.int/ healthinfo/survey/ageingdefnolder/en/index.html.
63. Young L. 2006. Post-herpetic neuralgia: A review of advances in treatment and prevention. J Drugs Dermatol, 5:939-42.